Keyphrases
Aspergillus
6%
Chronic Pulmonary Aspergillosis
15%
Clinical Outcomes
11%
Comorbidity
18%
COVID-19
76%
COVID-19 Cases
8%
COVID-19 Patients
21%
COVID-19 Vaccine
8%
Critically Ill Patients
6%
Emerging Infections
7%
Epidemiology
6%
Expert Review
8%
High-income Countries
8%
Hospital Admission
6%
Hospitalized Patients
14%
Indonesia
100%
Indonesian
8%
Intensive Care Unit
10%
International Cohort
9%
Invasive Mechanical Ventilation
6%
ISARIC
8%
Jakarta
36%
Latent Tuberculosis Infection
9%
Low-middle Income Countries
10%
Lung Cancer Patients
5%
Modul
7%
Mortality Prediction
6%
Multidrug-resistant Tuberculosis (MDR-TB)
34%
Pada
9%
Pandemi
6%
Patients with COVID-19
14%
Placebo
7%
Platform Trials
8%
Pulmonary Tuberculosis
29%
Quantitative PCR
10%
Randomized Controlled Trial
8%
Rapid Diagnostic Test
5%
Referral Hospital
6%
Risk Factors
6%
Severe Acute Respiratory Syndrome
7%
Severe COVID-19
13%
Streptococcus Pneumoniae
6%
TB Patients
11%
Treatment Outcome
8%
Tuberculosis
46%
Tuberculosis Patients
37%
Tuberculosis Treatment
13%
Usual Care
6%
Vaccine Effectiveness
12%
Xpert MTB
6%
Medicine and Dentistry
Acid Fast Bacterium
5%
Acute Respiratory Distress Syndrome
7%
Adverse Event
6%
Apoplexy
5%
Artificial Respiration
10%
Aspergillus
6%
Chronic Pulmonary Aspergillosis
9%
Clinical Feature
5%
Cohort Effect
7%
Comorbidity
15%
COVID-19
79%
Cross Sectional Study
5%
Culture Conversion
6%
Diabetes
5%
Diseases
17%
Drug Resistance
6%
Drug Resistant Tuberculosis
14%
Human Immunodeficiency Virus
9%
Infection
22%
Intensive Care
5%
Intensive Care Unit
12%
Interferon Gamma Release Assay
5%
Latent Tuberculosis
8%
Low and Middle Income Countries
8%
Lung Cancer
9%
Lung Tuberculosis
17%
Lymphocyte
6%
Mesenchymal Stem Cell
5%
Multidrug Resistant Tuberculosis
15%
Mycobacterium Tuberculosis
5%
Observational Study
12%
Platelet
5%
Pneumococcal Pneumonia
6%
Prevalence
6%
Public Health
9%
Randomized Controlled Trial
5%
Rapid Diagnostic Test
5%
Rifampicin
13%
Severe Acute Respiratory Syndrome Coronavirus 2
13%
Sputum
9%
Sputum Culture
9%
Streptococcus pneumonia
6%
Systematic Review
5%
Tuberculosis Treatment
6%
Pharmacology, Toxicology and Pharmaceutical Science
Adult Respiratory Distress Syndrome
5%
Adverse Event
10%
Aspergillus
10%
Clinical Feature
6%
Cohort Study
9%
Comorbidity
26%
Coronavirinae
20%
Coughing
5%
COVID-19 Vaccine
10%
Cross-Sectional Study
7%
Dexamethasone
5%
Diabetes Mellitus
8%
Diseases
34%
Drug Resistant Tuberculosis
14%
Dyspnea
6%
Elimination
6%
HIV
10%
Hospital Mortality
7%
Infection
29%
Isoniazid
5%
Latent Tuberculosis
11%
Linezolid
5%
Lung Aspergillosis
12%
Lung Tuberculosis
19%
Mortality Rate
5%
mRNA Vaccine
6%
Multi-Drug-Resistant Tuberculosis
12%
Oseltamivir
5%
Placebo
11%
Prevalence
5%
Randomized Controlled Trial
11%
Rifampicin
12%
SARS Coronavirus
16%
Tuberculous Meningitis
5%
